Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CPB1 | P15086 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17874 | 0.75 | TDP1 (0.43) | SMN1; SMN2SLC22A6TDP1CPB1MAPT | |
| SCHEMBL8948260 | 0.75 | TDP1 (0.50) | SMN1; SMN2SLC22A6TDP1CPB1MAPT | |
| SCHEMBL27959737 | 0.74 | SMN1; SMN2 (0.42) | SMN1; SMN2SLC22A6TDP1CPB1MAPT | |
| SCHEMBL630577 | 0.74 | TDP1 (0.48) | SMN1; SMN2SLC22A6TDP1CPB1ALDH1A1 | |
| SCHEMBL10729283 | 0.74 | TDP1 (0.48) | SMN1; SMN2SLC22A6TDP1CPB1ALDH1A1 | |
| SCHEMBL5188914 | 0.73 | TDP1 (0.42) | SMN1; SMN2SLC22A6TDP1CPB1MAPT | |
| SCHEMBL7720554 | 0.72 | TDP1 (0.46) | SMN1; SMN2SLC22A6TDP1CPB1ALDH1A1 | |
| Hydrogen Sulfide SCHEMBL11546403 | 0.72 | TDP1 (0.46) | SMN1; SMN2SLC22A6TDP1CPB1MAPT | |
| SCHEMBL11203316 | 0.71 | CPB1 (0.48) | SMN1; SMN2SLC22A6TDP1CPB1ALDH1A1 | |
| SCHEMBL11940979 | 0.71 | TDP1 (0.40) | SMN1; SMN2SLC22A6TDP1CPB1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11324713-B2 | Organoarsenic compounds and methods for the treatment of cancer | SOLASIA PHARMA K.K. (JP) | 2022-05-10 | — | — | US | disclosed |
| US-11324714-B2 | Organoarsenic compounds and methods for the treatment of cancer | SOLASIA PHARMA K.K. (JP) | 2022-05-10 | — | — | US | disclosed |
| US-11324713-B2 | Organoarsenic compounds and methods for the treatment of cancer | SOLASIA PHARMA K.K. (JP) | 2022-05-10 | — | — | US | disclosed |
| US-11324714-B2 | Organoarsenic compounds and methods for the treatment of cancer | SOLASIA PHARMA K.K. (JP) | 2022-05-10 | — | — | US | disclosed |
| EP-3388111-B1 | ORGANOARSENIC COMPOUND FOR THE TREATMENT OF CANCER | SOLASIA PHARMA K K (JP) | 2021-09-29 | — | — | EP | disclosed |
| US-20210038557-A1 | ORGANOARSENIC COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | SOLASIA PHARMA K.K. (JP) | 2021-02-11 | — | — | US | disclosed |
| US-20210038557-A1 | ORGANOARSENIC COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | SOLASIA PHARMA K.K. (JP) | 2021-02-11 | — | — | US | disclosed |
| US-20210038556-A1 | ORGANOARSENIC COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | SOLASIA PHARMA K.K. (JP) | 2021-02-11 | — | — | US | disclosed |
| US-20210038556-A1 | ORGANOARSENIC COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | SOLASIA PHARMA K.K. (JP) | 2021-02-11 | — | — | US | disclosed |
| US-10842769-B2 | Organoarsenic compounds and methods for the treatment of cancer | SOLASIA PHARMA K.K. (JP) | 2020-11-24 | — | — | US | disclosed |
| US-20050131062-A1 | S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2005-06-16 | — | — | US | disclosed |
| US-20050131062-A1 | S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2005-06-16 | — | — | US | disclosed |
| EP-1474128-A2 | S−DIMETHYLARSINO−THIOSUCCINIC ACID S−DIMETHYLARSINO−2−THIOBENZOIC ACID S−(DIMETHYLARSINO) GLUTATHIONE AS TREATMENTS FOR CANCER | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 2004-11-10 | — | — | EP | disclosed |
| EP-1474128-A2 | S−DIMETHYLARSINO−THIOSUCCINIC ACID S−DIMETHYLARSINO−2−THIOBENZOIC ACID S−(DIMETHYLARSINO) GLUTATHIONE AS TREATMENTS FOR CANCER | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003057012-A3 | S-DIMETHYLARSINO-THIOSUCCINIC ACID S-DIMETHYLARSINO-2-THIOBENZOIC ACID S-(DIMETHYLARSINO) GLUTATHIONE AS TREATMENTS FOR CANCER | UNIV TEXAS (US) | 2004-07-08 | — | — | WO | disclosed |
| WO-2003057012-A8 | S-DIMETHYLARSINO-THIOSUCCINIC ACID S-DIMETHYLARSINO-2-THIOBENZOIC ACID S-(DIMETHYLARSINO) GLUTATHIONE AS TREATMENTS FOR CANCER | UNIV TEXAS (US) | 2004-04-01 | — | — | WO | disclosed |
| US-20040034095-A1 | S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-02-19 | — | — | US | disclosed |
| US-20040034095-A1 | S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-02-19 | — | — | US | disclosed |
| WO-2003057012-A2 | S-DIMETHYLARSINO-THIOSUCCINIC ACID S-DIMETHYLARSINO-2-THIOBENZOIC ACID S-(DIMETHYLARSINO) GLUTATHIONE AS TREATMENTS FOR CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2003057012-A2 | S-DIMETHYLARSINO-THIOSUCCINIC ACID S-DIMETHYLARSINO-2-THIOBENZOIC ACID S-(DIMETHYLARSINO) GLUTATHIONE AS TREATMENTS FOR CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11324714-B2 | Organoarsenic compounds and methods for the treatment of cancer | GSS, CTH, MALT1 | SMN1; SMN2 4430/4885SLC22A6 1004/4885TDP1 1935/4885 |
| US-10842769-B2 | Organoarsenic compounds and methods for the treatment of cancer | GSS, CTH, MALT1 | SMN1; SMN2 4430/4885SLC22A6 1004/4885TDP1 1935/4885 |
| US-20050131062-A1 | S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer | AS3MT, GSTA1, GSTM1 | SMN1; SMN2 2188/4885SLC22A6 446/4885TDP1 1247/4885 |
| US-20210038556-A1 | ORGANOARSENIC COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | GSS, CTH, MALT1 | SMN1; SMN2 4430/4885SLC22A6 1004/4885TDP1 1935/4885 |
| US-20040034095-A1 | S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer | AS3MT, GSTA1, GSTM1 | SMN1; SMN2 2188/4885SLC22A6 446/4885TDP1 1247/4885 |
| US-20210038557-A1 | ORGANOARSENIC COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | GSS, CTH, MALT1 | SMN1; SMN2 4430/4885SLC22A6 1004/4885TDP1 1935/4885 |
| US-11324713-B2 | Organoarsenic compounds and methods for the treatment of cancer | GSS, CTH, MALT1 | SMN1; SMN2 4430/4885SLC22A6 1004/4885TDP1 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.